+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Gene Therapy Market Report and Forecast 2023-2031

  • PDF Icon


  • 147 Pages
  • May 2023
  • Region: Global
  • Expert Market Research
  • ID: 5797931
The global gene therapy market value was USD 6.36 billion in 2022 driven by the increasing prevalence of genetic disorders across the globe. The market size is anticipated to grow at a CAGR of 22.8% during the forecast period of 2023-2031 to achieve a value of USD 40.39 billion by 2031.

Gene Therapy Introduction

Gene therapy is a rapidly evolving field in medical science, offering innovative solutions for the treatment and management of various genetic disorders. It is a ground-breaking approach that involves the direct manipulation of an individual's genes to correct or replace faulty genetic information, ultimately mitigating or curing the associated medical condition. With the advent of advanced molecular biology and genetic engineering techniques, gene therapy has emerged as a promising alternative to traditional treatment methods, aiming to address the root causes of genetic diseases rather than just managing their symptoms.

The purpose of this report is to provide an overview of gene therapy, its underlying principles, and its potential applications. We will examine the different types of gene therapy, the methods employed to deliver therapeutic genetic material into target cells, and the safety and ethical concerns associated with this cutting-edge technology. Furthermore, we will explore the latest research and clinical trials that demonstrate the potential of gene therapy in treating a wide range of genetic disorders, including monogenic diseases, metabolic disorders, and certain types of cancer.

By presenting an in-depth analysis of gene therapy, this report aims to offer a comprehensive understanding of its current state and future prospects. With continued research and clinical trials, gene therapy holds immense potential to revolutionize the field of medicine and pave the way for personalized, precision-based treatments that address the unique genetic makeup of each individual patient.

Gene Therapy Market Scenario

The global gene therapy market has experienced substantial growth in recent years, driven by factors such as the increasing prevalence of genetic disorders, advancements in genetic engineering techniques, and a growing number of regulatory approvals for gene therapy products. As of September 2021, the market was projected to continue expanding at a rapid pace, with a compound annual growth rate (CAGR) ranging from 20% to 30% over the next several years.

Factors driving the growth of the gene therapy market included the rising prevalence of genetic disorders, advancements in genetic engineering techniques, and growing investments in research and development.

The gene therapy market faced challenges such as safety concerns, ethical issues, and high costs associated with gene therapy treatments.

Gene Therapy Market segmentations

Market Breakup by Therapy Type

  • In-Vivo Therapy
  • Ex-Vivo Therapy

Market Breakup by Indications

  • Acute Lymphoblastic Leukemia (ALL)
  • Inherited Retinal Disease
  • Large B-Cell Lymphoma
  • Melanoma
  • Beta-Thalassemia Major/SCD
  • Head & Neck Squamous Cell Carcinoma
  • Peripheral Arterial Disease
  • Spinal Muscular Atrophy (SMA)
  • Others

Market Breakup by Vector Type

Viral Vector

  • Lentiviral Vectors
  • Adeno-Associated Viral (Aav) Vectors
  • Retrovirus Vectors
  • Modified Herpes Simplex Virus
  • Adenovirus Vectors
  • Others
  • Non-Viral Vector

Market Breakup by Region

North America

  • United States of America
  • Canada


  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • Others

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Others

Middle East and Africa

  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Key Trends in the Gene Therapy Market

Some key trends of the market are as follows:
  • Regulatory Approvals: The increasing number of regulatory approvals for gene therapy products has been a significant trend, as it indicates the growing recognition and acceptance of these treatments by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA)
  • Strategic Collaborations and Partnerships: Companies and research institutions have been forming collaborations and partnerships to share resources, knowledge, and expertise. These collaborations aim to accelerate the development of gene therapy products, expand their pipelines, and enhance their market presence
  • Personalized Medicine: The gene therapy market has been increasingly focusing on personalized medicine, as it offers the potential to provide targeted and precise treatments based on an individual's unique genetic makeup. This approach is expected to improve treatment outcomes and reduce the risk of side effects
  • Advancements in Delivery Systems: Continued research and development have led to the emergence of new and more efficient gene delivery systems, such as viral and non-viral vectors, which play a crucial role in the success of gene therapy treatments
  • Focus on Rare Diseases: Many gene therapy companies have been concentrating on developing treatments for rare genetic diseases, often with limited treatment options. This focus has been driven by the high unmet medical needs, the potential for orphan drug designation, and the possibility of premium pricing for successful therapies
  • Expansion of Indications: Gene therapy was initially focused on monogenic diseases; however, its potential applications have expanded to include a wider range of conditions, such as various forms of cancer, neurological disorders, and metabolic diseases
  • Government and Private Funding: The gene therapy market has witnessed increased financial support from both government and private organizations. This funding has accelerated research and development, clinical trials, and commercialization of gene therapy products
  • Ethical and Regulatory Discussions: As gene therapy continues to advance, ethical and regulatory discussions surrounding its use have become more prominent. This includes topics such as germline editing, access to treatments, and the long-term safety of gene therapies

Gene Therapy Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
  • AstraZeneca
  • Boehringer Ingelheim International GmbH
  • GlaxoSmithKline plc
  • Novartis AG
  • CHIESI Farmaceutici SpA
  • Sunovion Pharmaceuticals Inc
  • Teva Pharmaceutical Industries Ltd
  • Mylan N.V., Orion Corporation
  • Merck & Co., Inc
  • Grifols, S.A
  • Abbott
  • F. Hoffmann-La Roche Ltd
  • Vectura Group plc
  • Pfizer Inc, Alkermes
  • Mylan N.V, Almirall, S.A, Genentech, Inc
  • Biogen
  • Astellas Pharma Inc

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Gene Therapy Market Overview
3.1 Global Gene Therapy Market Historical Value (2016-2022)
3.2 Global Gene Therapy Market Forecast Value (2023-2031)
4 Global Gene Therapy Market Landscape
4.1 Global Gene Therapy Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Gene Therapy Product Landscape
4.2.1 Analysis by Therapy Type
4.2.2 Analysis by Vector Type
4.2.3 Analysis by Indications
5 Global Gene Therapy Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Gene Therapy Market Segmentation
6.1 lobal Gene Therapy Market by Therapy Type
6.1.1 Market Overview
6.1.2 In-Vivo Therapy
6.1.3 Ex-Vivo Therapy
6.2 Global Gene Therapy Market by Indications
6.2.1 Market Overview
6.2.2 Acute Lymphoblastic Leukemia (ALL)
6.2.3 Inherited Retinal Disease
6.2.4 Large B-Cell Lymphoma
6.2.5 ADA-SCID
6.2.6 Melanoma
6.2.7 Beta-Thalassemia Major/SCD
6.2.8 Head & Neck Squamous Cell Carcinoma
6.2.9 Peripheral Arterial Disease
6.2.10 Spinal Muscular Atrophy (SMA)
6.2.11 Others
6.3 Global Gene Therapy Market by Vector Type
6.3.1 Market Overview
6.3.2 Viral Vector Lentiviral Vectors Adeno-Associated Viral (Aav) Vectors Retrovirus Vectors Modified Herpes Simplex Virus Adenovirus Vectors Others
6.3.3 Non-Viral Vector
6.4 Global Gene Therapy Market by Region
6.4.1 Market Overview
6.4.2 North America
6.4.3 Europe
6.4.4 Asia Pacific
6.4.5 Latin America
6.4.6 Middle East and Africa
7 North America Gene Therapy Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Gene Therapy Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Gene Therapy Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.6 Australia
9.7 Others
10 Latin America Gene Therapy Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Gene Therapy Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by Year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Clinical Trials Analysis
14.1 Analysis by Trial Registration Year
14.2 Analysis by Trial Status
14.3 Analysis by Trial Phase
14.4 Analysis by Therapeutic Area
14.5 Analysis by Geography
15 Funding Analysis
15.1 Analysis by Type of Funding
15.2 Analysis by Funding Amount
15.3 Analysis by Leading Players
15.4 Analysis by Leading Investors
15.5 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.5 Others
18 Supplier Landscape
18.1 AstraZeneca
18.1.1 Financial Analysis
18.1.2 Product Portfolio
18.1.3 Demographic Reach and Achievements
18.1.4 Mergers and Acquisitions
18.1.5 Certifications
18.2 Boehringer Ingelheim International GmbH
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Mergers and Acquisitions
18.2.5 Certifications
18.3 GlaxoSmithKline plc
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Mergers and Acquisitions
18.3.5 Certifications
18.4 Novartis AG
18.4.1 Financial Analysis
18.4.2 Product Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Mergers and Acquisitions
18.4.5 Certifications
18.5 CHIESI Farmaceutici SpA
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Mergers and Acquisitions
18.5.5 Certifications
18.6 Sunovion Pharmaceuticals Inc
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Mergers and Acquisitions
18.6.5 Certifications
18.7 Teva Pharmaceutical Industries Ltd
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Mergers and Acquisitions
18.8 Mylan N.V., Orion Corporation
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Mergers and Acquisitions
18.8.5 Certifications
18.9 Merck & Co., Inc.
18.9.1 Financial Analysis
18.9.2 Product Portfolio
18.9.3 Demographic Reach and Achievements
18.9.4 Mergers and Acquisitions
18.9.5 Certifications
18.10 Grifols, S.A.
18.10.1 Financial Analysis
18.10.2 Product Portfolio
18.10.3 Demographic Reach and Achievements
18.10.4 Mergers and Acquisitions
18.10.5 Certifications
18.11 Abbott
18.11.1 Financial Analysis
18.11.2 Product Portfolio
18.11.3 Demographic Reach and Achievements
18.11.4 Mergers and Acquisitions
18.11.5 Certifications
18.12 F. Hoffmann-La Roche Ltd
18.12.1 Financial Analysis
18.12.2 Product Portfolio
18.12.3 Demographic Reach and Achievements
18.12.4 Mergers and Acquisitions
18.12.5 Certifications
18.13 Vectura Group plc
18.13.1 Financial Analysis
18.13.2 Product Portfolio
18.13.3 Demographic Reach and Achievements
18.13.4 Mergers and Acquisitions
18.13.5 Certifications
18.14 Pfizer Inc, Alkermes
18.14.1 Financial Analysis
18.14.2 Product Portfolio
18.14.3 Demographic Reach and Achievements
18.14.4 Mergers and Acquisitions
18.14.5 Certifications
18.15 Mylan N.V, Almirall, S.A, Genentech, Inc
18.15.1 Financial Analysis
18.15.2 Product Portfolio
18.15.3 Demographic Reach and Achievements
18.15.4 Mergers and Acquisitions
18.15.5 Certifications
18.16 Biogen
18.16.1 Financial Analysis
18.16.2 Product Portfolio
18.16.3 Demographic Reach and Achievements
18.16.4 Mergers and Acquisitions
18.16.5 Certifications
18.17 Astellas Pharma Inc.
18.17.1 Financial Analysis
18.17.2 Product Portfolio
18.17.3 Demographic Reach and Achievements
18.17.4 Mergers and Acquisitions
18.17.5 Certifications
19 Global Gene Therapy Market- Distribution Model (Additional Insight)
19.1 Overview
19.2 Potential Distributors
19.3 Key Parameters for Distribution Partner Assessment
20 Key Opinion Leaders (KOL) Insights (Additional Insight)
21 Company Competitiveness Analysis (Additional Insight)
21.1 Very Small Companies
21.2 Small Companies
21.3 Mid-Sized Companies
21.4 Large Companies
21.5 Very Large Companies
22 Payment Methods (Additional Insight)
22.1 Government Funded
22.2 Private Insurance
22.3 Out-of-Pocket

Companies Mentioned

  • Astrazeneca
  • Boehringer Ingelheim International GmbH
  • GlaxoSmithKline plc
  • Novartis AG
  • Chiesi Farmaceutici Spa
  • Sunovion Pharmaceuticals Inc
  • Teva Pharmaceutical Industries Ltd
  • Mylan N.V. Orion Corporation
  • Merck & Co. Inc.
  • Grifols, S.A.
  • Abbott
  • F. Hoffmann-La Roche Ltd
  • Vectura Group plc
  • Pfizer Inc, Alkermes
  • Mylan N.V, Almirall, S.A, Genentech, Inc
  • Biogen
  • Astellas Pharma Inc.



Table Information